Kiadis Pharma NV has appointed Ray Barlow as chief business officer and Govert Schouten as head of innovation to help advance the company’s cell therapies for the treatment of liquid and solid tumours. Dr Barlow joins Kiadis from e-therapeutics Plc where he was chief executive and generated the company’s first commercial deals. Before that he worked at Amgen In as executive director of corporate development. He holds a PhD in macromolecular science from the University of Manchester and a BSc in chemistry from the University of Leeds, both in the UK.
Dr Schouten has been a business consultant and formerly head of business development of Crucell Vaccines which is now part of Johnson & Johnson Inc. He holds a PhD in tumour virology from Leiden University in the Netherlands.
Kiadis announced the appointments on 13 July 2020.
Copyright 2020 Evernow Publishing Ltd